fbpx Yourgene Health plc - Home
002-news.jpg
004-news.jpg
DSC00185r.jpg
003-news.jpg
001-news.jpg
previous arrow
next arrow

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Clarigene® SARS-CoV-2 Product Update
and Partnerships with CityDoc and ReCoVa-19

Manchester, UK – 11 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following the Company’s statement on 24 December 2020, regarding the new virus strain (VUI-202012/01 SARS-CoV-2 variant), Yourgene’s wet lab testing is now complete and has confirmed that the performance of the Clarigene® SARS-CoV-2 assay is not impacted by any currently known mutations in the VUI-202012/01 strain.

The wet lab testing followed a detailed in silico (Computer) analysis of the mutations in the new SARS-CoV-2 variant, to assess the reliability of Yourgene’s existing Clarigene® product. Unlike many other assays on the market, the Clarigene® SARS-CoV-2 assay does not rely on amplification of the S gene, where one of the key VUI-202012/01 variants (N501Y) is located, in this new virulent strain. The Company has also implemented an ongoing rigorous internal surveillance programme to ensure continued monitoring for the development of new viral strains. This includes database monitoring for SARS-CoV-2 variants with mutations in the N and the E gene which fall around the assay primers and probes, as well as impact assessment on these mutations on assay performance, evaluated by in silico analysis and wet lab confirmation.

Following the confirmation of the performance of the Clarigene® SARS-CoV-2 assay against the new virus strain, Yourgene have partnered with CityDoc Medical Limited (“CityDoc”), a 15-year old healthcare business and one of the UK’s largest private vaccination and medical testing companies with over 150+ clinics across the UK, to oversee the customer management and offer responsive clinical support for Yourgene’s Clarigene® test, for the UK Government’s Test To Release for international travellers scheme. CityDoc will manage the e-commerce function and logistics by allowing customers to order a sample collection kit and returning the test sample to the Yourgene laboratory. In addition, another key customer, ReCoVa-19 Limited works alongside Yourgene and CityDoc to provide access to their customer-facing COVID testing and wellness monitoring app, which enables sample tracking and customers to access their test results.

Lyn Rees, CEO of Yourgene commented: “We are pleased to confirm that our Clarigene® test is not compromised by the recently analysed mutations in the SARS-CoV-2 virus and believe that our ongoing internal surveillance for new virus strains shows our commitment to offering our customers the quality products they expect and deserve. We have a great and reliable product in the Clarigene® test and look forward to working with CityDoc and ReCoVa-19 Limited, in order to support the economy by aiding the travel industry’s return to normality.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122

This email address is being protected from spambots. You need JavaScript enabled to view it.

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie / Ludovico Lazzaretti

 Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Corporate Broker)
Aubrey Powell / Tom Salvesen / George Tzimas

Tel: +44 (0)20 7496 3000

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne 

Tel: +44 (0)20 7933 8780 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Mob: 07980 541 893 Mob: 07584 391 303   

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.

Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.




  • 28 September 2021 - AGM Statement Investor presentation +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    AGM Statement
    Investor presentation

    Manchester , UK - 28 September 2021 : Yourgene (AIM: YGEN), a leading international molecular diagnostic group, will be holding its Annual General Meeting (AGM) at 4:00pm today.  In-person registration for this meeting is now closed due to COVID-19 protocols in place but investors can still attend via the Investor Meet Company website as described at the end of this notice.

    At the meeting Adam Reynolds, Non-executive

    Read More
  • 10 September 2021 - Further re: DHSC contract secured to support COVID-19 surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Further re: DHSC contract secured to support COVID-19 surge testing

    Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract Award Notice has been published in relation to its contract with the Department of Health & Social Care (“DHSC”) for the provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing, as announced

    Read More
  • 1 September 2021 - Yourgene Genomic Services receive ISO 15189:2012 accreditation +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services receive ISO 15189:2012 accreditation
    Validating its COVID-19 testing and sequencing services, providing assurance of compliance to international standards to deliver quality levels of performance and competence

    Manchester, UK – 1 September 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following assessments by the UK accreditation service (UKAS), it has received ISO 15189:2012 accreditation for its COVID-19 testing and sequencing services,

    Read More
  • 1 September 2021 - Notice of AGM and Annual Report 2021 +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Notice of AGM and Annual Report 2021
    Investor presentation

    Manchester, UK 1 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that the Notice of Annual General Meeting (“AGM”) and Form of Proxy will shortly be available on the Company’s website at: www.yourgene-health.com/investors/key-documents/shareholder-communications  and are being posted to those shareholders who have opted out of electronic communications.

    The Annual Report and Accounts

    Read More
  • 19 August 2021 - Yourgene’s COVID-19 testing investment reaps rewards DHSC contract secured to support COVID-19 surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene’s COVID-19 testing investment reaps rewards
    DHSC contract secured to support COVID-19 surge testing

    Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, confirms that Yourgene Genomic Services (‘YGS’) has been awarded a contract for provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing by the Department of Health & Social Care (DHSC).

    In April

    Read More
  • 11 August 2021 - Earn-out Milestone, Issue of Equity & Total Voting Rights +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Earn-out Milestone, Issue of Equity & Total Voting Rights

    Manchester, UK 11 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces an issue of equity pursuant to the terms of the acquisition of Coastal ® Genomics Inc. ("Coastal") which completed in August 2020 (the “Acquisition”).

    Under the terms of the Coastal acquisition, a second strategic partnership Coastal Genomics’ Ranger ® technology was announced on

    Read More
  • 11 August 2021 - Audited Final results and unaudited Q1 business update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Audited Final results and unaudited Q1 business update

    Manchester, UK – 11 August 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its full year financial results for the year ended 31 March 2021 (“FY21”), and provides a business update after its first trading quarter of the current financial year (Q1).

    The FY21 results, delivered in-line with prior guidance, reflect resilient revenue growth through the

    Read More
  • 21 June 2021 - Second Strategic Partner for Coastal Genomics +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Second Strategic Partner for Coastal Genomics

    Manchester, UK – 21 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Inc., the Company’s wholly-owned US subsidiary, has signed a Master Supply Agreement (“MSA”) (the “Agreement”) with a leading US laboratory services provider (“the Partner”). The Agreement provides the Partner with non-exclusive use of the Group’s Ranger TM Technology, which was acquired with

    Read More
  • 18 June 2021 - Contract Award for the supply of DPYD testing kits to NHS Wales +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Contract Award for the supply of DPYD testing kits to NHS Wales
    Estimated to be worth £232,000 across two years

     

    Manchester, UK –  June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has been awarded the contract to supply its Elucigene DPYD testing kits to NHS Wales. The contract award is for two years (for a period of 12 months with

    Read More
  • 9 June 2021 - Multi-year licence and supply agreement with leading US precision medicine company +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Multi-year licence and supply agreement with leading US precision medicine company

    Manchester, UK – 9 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has entered into a licence and supply agreement (the “Agreement”) with a leading US precision medicine company (the “Partner”) for an initial term of three years commencing  1 April 2022. The Agreement grants the Partner a non-exclusive licence to

    Read More
  • 19 May 2021 - Distribution Partnership for the Middle East and Africa +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Distribution Partnership for the Middle East and Africa
    Yourgene and Alliance Global launch partnership across multiple territories

    Manchester, UK – 19 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it is launching a Distribution Partnership with Dubai-headquartered Alliance Global FZ LLC (‘AGBL’ or ‘Alliance Global’) across a broad range of territories in the Middle East and Africa to expand the Company’s geographical

    Read More
  • 18 May 2021 - Launch of IONA® Care NIPT service offering +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Launch of IONA ® Care NIPT service offering
    Extended clinical menu to screen SCAs and AAs for pregnant women

    Manchester, UK – 18 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA ® Care, a non-invasive prenatal test (NIPT) service offering, with an extended clinical menu measuring the likelihood that a pregnant woman is carrying a fetus with sex chromosome aneuploidies (SCA

    Read More
  • 17 May 2021 - Further testing service agreement for MyHealthChecked plc +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services to support MHC’s second Boots agreement for Day 2 & Day 8 testing
    for international arrivals to the UK 

    Manchester, UK – 17 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partner MyHealthChecked plc (AIM:MHC) (“MyHealthChecked”) has signed a second COVID-19 testing services agreement, to support the supply of the MyHealthChecked™ COVID-19 at-home nasal swab kit, PCR laboratory

    Read More
  • 29 April 2021 - Full year Trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Full year Trading update
    10% year-on-year revenue growth

    Manchester, UK – 29 April 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the financial year ended 31 March 2021 (“FY 2021”).

    Yourgene reports unaudited revenues for FY 2021 of £18.3m (FY 2020: £16.6m), up 10% compared to the previous year.  This is in line with recently issued guidance and reflects

    Read More
  • 26 April 2021 - Further National Microbiology Framework contract awards +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Further National Microbiology Framework contract awards

    Successful tenders under Lots 2 & 3 valued at a total of £4bn
    Yourgene one of only three companies to have been successfully awarded under all four lots

    Manchester, UK – 26 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Public Health England (“PHE”) has confirmed that Yourgene has been successful with its tenders under PHE’s

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen